Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital

Transcorneal electrical stimulation for the treatment of retinitis pigmentosa - a multicenter safety study of the OkuStim® System (TESOLA-study)

Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review


  1. Sensitive Assessment of Acute Optic Neuritis by a New, Digital Flicker Test

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  2. Can DMCO Detect Visual Field Loss in Neurological Patients? A Secondary Validation Study

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Aquaporin-1 Expression in Retinal Pigment Epithelial Cells Overlying Retinal Drusen

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  1. Oliver McFarlane syndrome: two new cases and a review of the literature

    Publikation: Bidrag til tidsskriftReviewpeer review

  2. Retinal Structure in RPE65-Associated Retinal Dystrophy

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  3. Gentagne diploid biparental molae

    Publikation: Bidrag til tidsskriftTidsskriftartikelpeer review

  • Jasleen K Jolly
  • Siegfried K Wagner
  • Peter Martus
  • Robert E MacLaren
  • Barbara Wilhelm
  • Andrew R Webster
  • Susan M Downes
  • Peter Charbel Issa
  • Ulrich Kellner
  • Herbert Jägle
  • Klaus Rüther
  • Mette Bertelsen
  • Ragnheiður Bragadóttir
  • Josephine Prener Holtan
  • Ingeborgh van den Born
  • Andrea Sodi
  • Gianni Virgili
  • Mariya Gosheva
  • Johanna Pach
  • Ida Zündorf
  • Eberhart Zrenner
  • Florian Gekeler
Vis graf over relationer

Background: Transcorneal electrical stimulation (TES) has been suggested as a possible treatment for retinitis pigmentosa (RP). Objective: To expand the safety assessment of repeated applications of an electrical current from a DTL-like electrode in patients with RP. Methods: This single-Arm open label interventional safety trial included a total of 105 RP patients from 11 European centers, who received weekly TES for 6 months on 1 eye followed by observation for another 6 months without stimulation. The primary outcome measure was safety, indicated by the frequency and severity of adverse events. Secondary measures included intraocular pres-sure and central retinal thickness. Visual field and visual acuity were examined using the methods available at each site. Results: Dry eye sensation was the most common adverse event recorded (37.5%). Serious adverse events secondary to TES were not observed. Most adverse events were mild and all resolved without sequelae. The secondary outcome measures revealed no significant or clinically relevant changes. Conclusion: The present results confirm the excellent safety profile of TES. Transient dry eye symptoms were the most common adverse event.

TidsskriftOphthalmic Research
Udgave nummer3
Sider (fra-til)234-243
Antal sider10
StatusUdgivet - maj 2020

ID: 58959305